According to a new report, published by KBV research, The Global Transdermal Patches Market size is expected to reach $8.5 billion by 2030, rising at a market growth of 5.1% CAGR during the forecast period. In the year 2022, the market attained a volume of 33,59,966.8 thousand units, experiencing a growth of 4.6% (2019-2022).
The Hospitals & Clinics segment would experience a CAGR of 6.4% during (2023 - 2030). Hospitals and clinics increasingly rely on transdermal patches to manage chronic diseases. Transdermal patches provide a convenient and patient-friendly approach for long-term drug administration, particularly in cases where patients need continuous medication for conditions such as hypertension, diabetes, and chronic pain. The sustained release offered by transdermal patches aligns well with the requirements of chronic disease management. These factors will boost the demand in the segment.
The Hospital Pharmacies segment is registering the maximum revenue in the Global Transdermal Patches Market by Distribution Channel in 2022; thereby, achieving a market value of $3.3 billion by 2030. As the applications of transdermal patches expand to cover a wider range of therapeutic areas, hospitals are increasingly incorporating these patches into their formularies. Transdermal patches are now available for various medications, including pain management, hormone therapy, cardiovascular conditions, and neurology, making them valuable additions to hospital pharmacy offerings. As a result, there will be increased growth in the segment.
The Silicone Adhesives segment would exhibit a CAGR of 5.3% during (2023 - 2030). Silicone adhesives are known for their skin-friendly properties. They provide gentle adhesion to the skin, minimizing the risk of irritation or discomfort. This attribute is crucial for transdermal patches, as patient comfort and adherence to treatment regimens are significant considerations in pharmaceutical product development. Silicone adhesives exhibit excellent flexibility and conformability, allowing transdermal patches to adhere securely to various skin surfaces.
The Drug-In-Adhesive segment is generating highest revenue in the Global Transdermal Patches Market by Patch Type in 2022; thereby, achieving a market value of $4.2 billion by 2030. Drug-in-adhesive patches are known for their simplicity, as the drug is embedded directly within the adhesive layer. This design simplifies the patch application process, making it user-friendly and convenient for patients. The straightforward application contributes to increased patient compliance. These factors will boost the demand in the segment.
The Smoking Cessation segment is experiencing a CAGR of 4.8% during (2023 - 2030). The growing awareness of smoking-related health concerns, including cardiovascular diseases, respiratory issues, and various cancers, has motivated individuals to quit smoking. Transdermal patches, as a form of NRT, offer a controlled and sustained release of nicotine, helping individuals manage withdrawal symptoms and quit smoking gradually. Therefore, the segment will expand rapidly in the coming years.
The North America region is leading the segment in the Global Transdermal Patches Market by Region in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $3.0 billion by 2030. The Europe region is poised to grow at a CAGR of 4.7% during (2023 - 2030). Additionally, The Asia Pacific region would witness a CAGR of 6% during (2023 - 2030).
Full Report: https://www.kbvresearch.com/transdermal-patches-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Johnson & Johnson, Viatris, Inc. (Mylan N.V.), Boehringer Ingelheim International GmbH, Endo International PLC, Bayer AG, Nitto Denko Corporation, Cipla Limited, Amneal Pharmaceuticals, Inc., Novartis AG, and AbbVie, Inc.
By End User (Volume, Thousand Units, USD Billion, 2019-2030)
By Distribution Channel (Volume, Thousand Units, USD Billion, 2019-2030)
By Adhesive Type (Volume, Thousand Units, USD Billion, 2019-2030)
By Patch Type (Volume, Thousand Units, USD Billion, 2019-2030)
By Application (Volume, Thousand Units, USD Billion, 2019-2030)
By Geography (Volume, Thousand Units, USD Billion, 2019-2030)
Companies Profiled
Unique Offerings 
